Partnering
Better Together
Partnering with Fortvita Biologics
Fortvita Biologics seeks strategic partnerships to accelerate the development and global accessibility of breakthrough therapies for patients worldwide. Building on our strong foundation in oncology and expanding therapeutic areas, we collaborate with biopharma and biotech companies with the aim of addressing critical unmet medical needs across multiple disease areas.
Our partnerships leverage Fortvita’s expertise in immuno-oncology and antibody-drug conjugates, combining advanced science with proprietary technologies to develop targeted, next-generation therapies. Backed by a dedicated R&D team and extensive preclinical and clinical experience, we continue to expand into cardiovascular and metabolic medicine, autoimmune diseases, and ophthalmology, translating innovative science into meaningful solutions for patients globally.
Our Partnership Approach
Global Development Collaborations
We collaborate with leading pharmaceutical and biotechnology companies to accelerate the development of our pipeline assets. These strategic partnerships combine our innovative investigational therapies with our partners’ global infrastructure, enabling efficient, data-driven clinical development and expanding access to potential new treatments for patients worldwide.
Research & Discovery Alliances
Our scientific expertise in novel bispecific antibodies and antibody-drug conjugates (ADCs) provides a strong foundation for impactful early-stage research collaborations. We actively welcome partnerships to explore new therapeutic targets, combination strategies, and breakthrough treatment modalities that have the potential to transform patient care.
Access & Distribution Partnerships
We seek partners with established distribution networks and strong market expertise across key global regions to help fulfill our mission of expanding access to life-changing therapies. By collaborating beyond traditional markets, we aim to bring innovative treatments to patients worldwide more efficiently and effectively.
Why Partner with Fortvita?
Advanced Pipeline & Regulatory Momentum
Our pipeline includes promising clinical-stage assets with demonstrated efficacy, including IBI363 (PD-1/IL-2α bispecific), IBI343 (CLDN18.2 ADC), and IBI3009 (DLL3-targeted ADC). These programs have received important regulatory designations, including Breakthrough Therapy Designation and Fast Track Designation, potentially accelerating development timelines.
Global Perspective & Expertise
With a strong foundation of biopharmaceutical success and an expanded global mission, Fortvita Biologics brings valuable expertise in advancing therapies across diverse markets. Our team has deep experience in oncology drug development, with specialized capabilities in bispecific antibodies, ADCs, and immunotherapies—enabling us to drive innovative treatments from discovery through clinical development.
Flexible Partnership Models
We offer flexible collaboration models tailored to each partner’s unique needs and program objectives, from full global development and commercialization partnerships to regional licensing agreements and focused research collaborations.
Let’s Work Together
Partnership Opportunities
Global and regional development and commercialization partnerships for our clinical-stage oncology assets
Research collaborations exploring novel combination strategies for our immunotherapy platforms
Manufacturing and supply chain partnerships to support global accessibility initiatives
Academic and research institution collaborations to explore new therapeutic applications
